Beam Therapeutics (BEAM) AI Stock Analysis

• Market Cap: $3.28B
• Dividend Yield: N/A
• Average Volume (3M): 1.57M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.05
• Revenue Growth: -84.07%
• EPS Growth: -157.71%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.33
• Shares Outstanding: 101,474,945
• 10 Day Avg. Volume: 1,270,251
• 30 Day Avg. Volume: 1,574,013
• PEG Ratio: 0.42
• Price to Book (P/B): 2.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.61
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 122.33
• Enterprise Value/Gross Profit: -11.01
• Enterprise Value/Ebitda: -42.18
• 1Y Price Target: $48.75
• Price Target Upside: 50.98% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: $34.00 ▲(5.30% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

BEAM’s score reflects a strong balance sheet and positive, well-defined pipeline/financing updates from the latest earnings call, supported by constructive technical momentum. These positives are tempered by very weak current operating fundamentals (large losses and heavy cash burn) and limited support from traditional valuation metrics given negative earnings.

Positive Factors

Strong cash runway

A $1.25B cash base plus an up-to-$500M non-dilutive facility materially extends execution runway into mid-2029. This durable funding cushion reduces near-term dilution risk and gives management time to advance multiple programs toward IND/BLA milestones and potential value inflection points.

Proprietary LNP and manufacturing

Owning LNP chemistry and GMP manufacturing creates a sustained operational advantage for in vivo programs. Control of delivery and scale supports outpatient IV dosing, redosing and faster CMC timelines, lowering partner/CMO dependency and improving chances of commercial readiness if clinical efficacy is proven.

Validated IP and partnerships

A standby patent license and a Pfizer exclusive license signal durable IP protection and external validation. Such arrangements both secure core rights and create near-term non-dilutive revenue/milestone pathways, strengthening long-term platform monetization options and partner-driven de-risking.

Negative Factors

High cash burn

Persistently negative operating and free cash flow (~-$345M TTM) and sharply lower revenues imply ongoing funding needs beyond existing cash if programs extend. This structural burn rate increases reliance on milestone financing or partnerships and makes sustained execution conditional on non-operating capital events.

Variant diversity & regulatory ambiguity

Extensive PAH variant diversity and unclear FDA guidance create structural challenges for a single broad IND. Numerous mutation-specific editors raise development complexity, higher per-patient costs and require novel regulatory pathways, slowing scalable commercialization and increasing execution risk.

Milestone‑tied financing risk

The non-dilutive facility extends runway but is conditional and secured by company assets, with principal due in 2033. Reliance on milestone triggers and covenants can constrain strategic flexibility, tie funding to program outcomes and create long-term repayment obligations that affect capital allocation decisions.

Beam Therapeutics Business Overview & Revenue Model

Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Beam Therapeutics generates revenue through a combination of research and development collaborations, licensing agreements, and potential future product sales. The company partners with pharmaceutical companies and research institutions to co-develop its therapies, often receiving upfront payments, milestone payments as projects advance, and royalties on future sales. Additionally, Beam may monetize its proprietary technologies through licensing deals, allowing other companies to use their base editing technology in exchange for fees. As their product candidates advance through clinical trials and toward commercialization, potential sales of successful therapies will also contribute to revenue.

Beam Therapeutics Financial Statement Overview

Summary

Financials are mixed: a strong balance sheet with modest leverage (debt-to-equity ~0.16) is offset by weak operating fundamentals, including sharply lower TTM revenue (~$25.6M, down ~54% YoY), a sizable TTM net loss (~$80M), and heavy cash burn (TTM operating cash flow about -$345.1M; free cash flow about -$360.0M) that implies ongoing funding needs.

Income Statement

Profitability remains weak. In TTM (Trailing-Twelve-Months), revenue fell sharply to $25.6M (down ~54% year over year) and the company posted a net loss of ~$80.0M, with deeply negative margins. While the TTM net loss is smaller than the 2024 loss (~$376.7M) and results improved versus some prior years, earnings quality is still pressured by heavy operating losses and inconsistent revenue levels (notably the spike in 2023 followed by a steep decline).

Balance Sheet

The balance sheet is a relative strength. Leverage is modest with total debt of ~$154.1M against stockholders’ equity of ~$1.24B in TTM (Trailing-Twelve-Months) (debt-to-equity ~0.16), and total assets are ~$1.48B. The key weakness is continued negative returns on equity (TTM return on equity around -0.43), reflecting ongoing losses despite a solid equity base.

Cash Flow

Cash burn is significant. TTM (Trailing-Twelve-Months) operating cash flow was about -$345.1M and free cash flow about -$360.0M, indicating substantial ongoing funding needs. Cash flow does loosely track earnings directionally (free cash flow to net income ~1.04 in TTM), but the core issue is persistently negative operating and free cash flow, with limited evidence of durable improvement versus prior years.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	63.52M	377.71M	60.92M	51.84M
Gross Profit	0.00	-304.04M	377.71M	-250.67M	-180.29M
EBITDA	-29.92M	-393.64M	-146.95M	-324.33M	-230.06M
Net Income	-79.99M	-376.74M	-132.53M	-289.09M	-370.64M
Balance Sheet
Total Assets	1.48B	1.10B	1.46B	1.34B	1.47B
Cash, Cash Equivalents and Short-Term Investments	1.25B	850.74M	1.19B	1.08B	965.65M
Total Debt	154.12M	161.43M	172.69M	179.00M	147.64M
Total Liabilities	242.82M	370.28M	478.38M	608.24M	647.72M
Stockholders Equity	1.24B	733.54M	981.33M	733.47M	826.74M
Cash Flow
Free Cash Flow	-360.05M	-356.19M	-182.93M	-26.42M	-113.08M
Operating Cash Flow	-345.10M	-347.25M	-149.19M	22.53M	-66.27M
Investing Cash Flow	-121.44M	185.01M	71.84M	-461.34M	-294.14M
Financing Cash Flow	478.05M	7.74M	276.45M	111.59M	756.14M

Beam Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 32.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Positive. The current price of 32.29 is above the 20-day moving average (MA) of 27.84, above the 50-day MA of 28.63, and above the 200-day MA of 22.87, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 64.11 is Neutral, neither overbought nor oversold. The STOCH value of 76.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BEAM.

Beam Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BEAM	63 Neutral	$3.28B	-7.28	-47.19%	―	-84.07%	-157.71%
IMVT	62 Neutral	$5.57B	-10.21	-69.35%	―	―	-27.70%
ARQT	60 Neutral	$3.30B	-76.11	-28.17%	―	129.21%	80.35%
DNLI	54 Neutral	$3.35B	-7.36	-44.44%	―	―	-5.30%
IMCR	53 Neutral	$1.70B	-57.64	-7.52%	―	27.51%	38.72%
IRON	52 Neutral	$2.50B	-12.36	-34.78%	―	―	-34.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Beam Therapeutics Corporate Events

Beam Therapeutics Secures $500 Million Credit Facility

On February 24, 2026, Beam Therapeutics reported fourth-quarter and full-year 2025 financial results, showing cash, cash equivalents and marketable securities of $1.25 billion at year-end, up from $850.7 million a year earlier, alongside higher annual R&D spending of $409.6 million. The company reiterated 2026 milestones across its liver and hematology franchises, including updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency in the first quarter and initial clinical data for BEAM-301 in glycogen storage disease type Ia later in the year.

Beam expanded its liver-targeted portfolio with BEAM-304, a new base-editing program for phenylketonuria that aims to durably correct PAH gene mutations via lipid nanoparticle delivery, with an IND filing planned in 2026 and a Phase 1/2 trial designed to address multiple mutation-specific editors. In hematology, updated Phase 1/2 BEACON data continued to support a potentially best-in-class profile for risto-cel in sickle cell disease, with manufacturing for all clinical doses completed and a U.S. BLA submission targeted as early as year-end 2026.

To support its late-stage pipeline, Beam on February 24, 2026, entered a senior secured credit facility of up to $500 million with Sixth Street, providing long-term, non-dilutive capital linked to risto-cel regulatory and commercial milestones and extending expected cash runway into mid-2029. The facility includes $100 million funded at closing, a further $300 million tied to specified achievements, and an additional $100 million available by mutual agreement, and is secured by substantially all company assets, with covenants around liquidity, indebtedness, and commercialization of risto-cel.

Beam also highlighted the December 2025 transition of its four-year in vivo base-editing collaboration with Pfizer, under which Pfizer opted for an exclusive worldwide license to a liver-targeted development candidate using Beam’s LNP delivery, assuming full development and commercialization control. Beam remains eligible for milestone payments and retains an option, after Phase 1/2, to co-develop and co-commercialize globally under a profit- and cost-sharing arrangement, reinforcing the platform’s external validation and potential future revenue streams.

The most recent analyst rating on (BEAM) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.

Beam Therapeutics Secures Standby License for Key Patents

On February 9, 2026, Beam Therapeutics entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. to secure continued access to certain gene-editing patents originally licensed by Bio Palette from Kobe. The arrangement ensures Beam will receive a direct, exclusive license from Kobe to practice these patents if the original Kobe–Bio Palette license ends under specified conditions, with Beam agreeing to pay Kobe the financial amounts it would otherwise owe to Bio Palette under the existing sublicense terms.

This structure is designed to protect Beam’s core intellectual property position and reduce licensing risk around critical patents underpinning its base-editing programs. By putting this contingency in place, Beam strengthens the durability of its IP rights and operational continuity, which may be important for partners, investors, and other stakeholders relying on the stability of its gene-editing platform.

The most recent analyst rating on (BEAM) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.

Beam Therapeutics announces upcoming board member resignation

On January 31, 2026, Beam Therapeutics Inc. announced that board member Dr. Carole Ho had submitted her resignation from the company’s Board of Directors, effective February 27, 2026. The company noted that Dr. Ho’s departure was not due to any disagreement regarding Beam’s operations, policies, or practices, suggesting an orderly governance transition rather than a sign of internal conflict for stakeholders to worry about.

The most recent analyst rating on (BEAM) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.

Beam Therapeutics outlines 2026 strategy and extends runway

On January 11, 2026, Beam Therapeutics outlined strategic priorities for 2026 across its genetic disease and hematology franchises, emphasizing progress in late-stage clinical programs and a substantially extended cash runway. The company reported clinical proof of concept for BEAM-302 in alpha-1 antitrypsin deficiency, treating more than 25 patients in an ongoing Phase 1/2 trial and securing U.S. FDA alignment on a potential accelerated approval pathway based on 12‑month biomarker endpoints, alongside inclusion of the program in the FDA’s CMC Development and Readiness Pilot. Beam is also advancing BEAM-301 for glycogen storage disease type Ia with a Phase 1/2 trial underway and initial data expected in 2026, and plans to disclose an additional liver-targeted program in the first half of 2026. In its hematology franchise, the company highlighted encouraging Phase 1/2 BEACON data for its sickle cell therapy risto-cel, which has fully enrolled adult and adolescent cohorts, completed manufacturing of all doses by December 2025, gained entry into the FDA’s CDRP program, and is being positioned for a biologics license application as early as year‑end 2026. Beam is simultaneously investing in next-generation in vivo gene-editing approaches for sickle cell disease, including targeted lipid nanoparticles for hematopoietic stem cell delivery and its ESCAPE platform, with a Phase 1 trial of the conditioning antibody BEAM‑103 expected to complete dosing in the first half of 2026. Financially, Beam estimated it ended 2025 with about $1.25 billion in cash, cash equivalents and marketable securities, supported in part by proceeds from Bristol-Myers Squibb’s acquisition of Orbital Therapeutics, and now projects its operating runway to extend into 2029, backing the anticipated commercial transition for risto-cel and pivotal development of BEAM‑302 and reinforcing its position as a well-capitalized emerging leader in genetic medicines.

The most recent analyst rating on (BEAM) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.

Beam Therapeutics Gains $255M from Orbital Acquisition

On December 8, 2025, Bristol-Myers Squibb completed its acquisition of Orbital Therapeutics, in which Beam Therapeutics held a 17% stake. Beam’s shares were converted into $255.1 million in cash, with potential for additional consideration, impacting its financial outlook ahead of the 2026 J.P. Morgan Healthcare Conference.

The most recent analyst rating on (BEAM) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.